3 days Ago By ABMN Staff
Connect Biopharma Holdings Limited ( NASDAQ:CNTB – Get Free Report ) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 87,800 shares, an increase of 53.5% from the November 30th total of 57,200 shares.
Currently, 0.2% of the company’s shares are short sold. Based on an average trading volume of 28,200 shares, the days-to-cover ratio is presently 3.
1 days. Connect Biopharma Price Performance Shares of NASDAQ CNTB opened at $1.14 on Monday.
The firm has a fifty day moving average of $1.09 and a 200-day moving average of $1.21.
Connect Biopharma has a 52-week low of $0.90 and a 52-week high of $2.66.
Analyst Ratings Changes Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Connect Biopharma in a report on Friday, September 6th. Institutional Investors Weigh In On Connect Biopharma An institutional investor recently raised its position in Connect Biopharma stock.
BML Capital Management LLC grew its position in Connect Biopharma Holdings Limited ( NASDAQ:CNTB – Free Report ) by 2.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,093,232 shares of the company’s stock after purchasing an additional 49,984 shares during the period.
Connect Biopharma makes up approximately 1.8% of BML Capital Management LLC’s holdings, making the stock its 13th largest holding. BML Capital Management LLC owned approximately 3.
79% of Connect Biopharma worth $3,014,000 at the end of the most recent quarter. 58.72% of the stock is owned by hedge funds and other institutional investors.
About Connect Biopharma ( Get Free Report ) Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Read More Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
